⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CLLS News
Cellectis S.A. American Depositary Shares
Celltaxis Names Co-Founder Eileen Heffernan as CEO to Accelerate Growth and Expand Leadership in Lymphatic Disease Therapeutics
prnewswire.com
CLLS
Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress
globenewswire.com
CLLS
Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL
globenewswire.com
CLLS
Cellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026
globenewswire.com
CLLS
Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress
globenewswire.com
CLLS
Cellectis Reports Financial Results for the First Quarter 2026
globenewswire.com
CLLS
Cellectis to Report First Quarter Financial Results on May 11, 2026
globenewswire.com
CLLS
Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting
globenewswire.com
CLLS
Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform
globenewswire.com
CLLS
ALLO
Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update
globenewswire.com
CLLS